Drug Trial Radar · NCT06891066
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Last checked: Nov 19, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Apr 14, 2025
Primary completion
Aug 10, 2027
Study completion Sep 30, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it.
Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISLDrug
ISL 1mg oral capsule will be administered as 2mg orally (each capsule 1mg) as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks.
ULODrug
ULO 100mg oral tablet will be administered as 200mg (2 tablets) orally as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks.
BIC/FTC/TAFDrug
BIC 50mg oral tablet/FTC 200mg oral tablet/TAF 25 mg oral tablet administered orally to group 2 participants for 48 weeks in part 1 of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With HIV-1 RNA ≥50 copies/mL at Week 24Time frame: Week 24
- Percentage of Participants who Experience an Adverse Event (AE)Time frame: Up to ~ 96 weeks
- Percentage of Participants Discontinuing Study Treatment due to AEsTime frame: Up to ~ 96 weeks
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Zuckerberg San Francisco General Hospital and Trauma Center ( Site 4107)
San Francisco, California
Mills Clinical Research ( Site 4109)
West Hollywood, California
Georgetown University Medical Center ( Site 4106)
Washington D.C., District of Columbia
Orlando Immunology Center ( Site 4103)
Orlando, Florida
Triple O Research Institute ( Site 4111)
West Palm Beach, Florida
Chatham County Health Department - Chatham CARE Center ( Site 4116)
Savannah, Georgia
KC CARE Health Center ( Site 4101)
Kansas City, Missouri
Regional Center for Infectious Diseases ( Site 4115)
Greensboro, North Carolina
Central Texas Clinical Research ( Site 4100)
Austin, Texas
Prism Health North Texas, Oak Cliff Health Center ( Site 4114)
Dallas, Texas
DCOL Center for Clinical Research ( Site 4112)
Longview, Texas
Momentum Clinical Research - Darlinghurst ( Site 4260)
Darlinghurst, New South Wales, Australia
St. Vincent's Hospital ( Site 4263)
Darlinghurst, New South Wales, Australia
Momentum Clinical Research Fortitude Valley ( Site 4261)
Fortitude Valley, Queensland, Australia
The Alfred Hospital ( Site 4264)
Melbourne, Victoria, Australia
Prahran Market Clinic ( Site 4262)
Prahran, Victoria, Australia
Ponce Medical School Foundation Inc./CAIMED Center ( Site 4301)
Ponce, Puerto Rico
Clinical Research Puerto Rico ( Site 4300)
San Juan, Puerto Rico
HOPE Clinical Research ( Site 4303)
San Juan, Puerto Rico
University Hospital Basel-Infectiology ( Site 4402)
Basel, Canton of Basel-City, Switzerland
Inselspital Bern-Inselspital Infektiologie ( Site 4403)
Bern, Canton of Bern, Switzerland
Hôpitaux Universitaires de Genève (HUG)-Infectious Disease Department ( Site 4404)
Geneva, Canton of Geneva, Switzerland
Ospedale Regionale di Lugano, Sede Civico-Servizio Malattie Infettive ( Site 4405)
Lugano, Canton Ticino, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.